Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Cardiotoxicity in Ibrutinib-Treated Patients: Incidence, Management, and Impact on Treatment Outcomes
Session:
SESSÃO DE POSTERS 11 - CARDIONCOLOGIA DE PONTA II
Speaker:
Ricardo Carvalheiro
Congress:
CPC 2025
Topic:
K. Cardiovascular Disease In Special Populations
Theme:
30. Cardiovascular Disease in Special Populations
Subtheme:
30.6 Cardio-Oncology
Session Type:
Cartazes
FP Number:
---
Authors:
Ricardo Carvalheiro; Leonor Magalhães; Isabel Cardoso; Vera Vaz Ferreira; Luís Almeida Morais; Tânia Mano; Rui Cruz Ferreira
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Introduction:</strong> Ibrutinib, a Bruton's tyrosine kinase inhibitor, has revolutionized treatment for various hematologic malignancies but is associated with cardiovascular toxicities (CTR-CVT), particularly atrial fibrillation (AF) and hypertension (HTN). Understanding the incidence, severity, and clinical impact of CTR-CVT is critical for optimizing treatment and improving patient outcomes.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Methods:</strong> We retrospectively evaluated a cohort of patients treated with ibrutinib in a single tertiary center.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Results:</strong> 54 pts (41% female) with a mean age of 68 ± 12 years were included in the analysis. 18 pts (33%) developed CTR-CVT during a median follow-up of 15 (IQR: 5-34) months, with a median time to cardiotoxicity of 10 (IQR: 1-19) months. There were 6 pts (13%) with new onset/worsening HTN, 10 pts (10%) with new-onset AF, and 6 pts (13%) with new onset/worsening heart failure (HF).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">Regarding risk factors for CTR-CVT, HTN, smoking, and previous HF were more frequent in the CTR-CVT group (78% vs 36%, p = 0.008; 22% vs 3%, p = 0.010; 28% vs 3%, p = 0.013, respectively). </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">AF occurred in a median of 8 (IQR: 1, 25) months after treatment initiation, with most of the cases (7 – 70%) being asymptomatic, and 2 (20%) requiring emergency hospital admission. Despite a mean CHA2DS2-VASc score of 3 ± 2, only 4 pts (40%) were started on oral anticoagulation, all with reduced doses. There were no thromboembolic or haemorrhagic events in this group. Considering other CTR-CVT, most events were mild, with 2 cases of CTCAE-grade >2 HTN and 1 case of grade 3 HF.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif">17 pts (32%) suspended ibrutinib after a median of 8 (IQR: 4, 19) months, with only 2 cases directly attributable to CTR-CVT. Kaplan-Meier analysis showed no significant differences between the groups regarding time to suspension of ibrutinib over 24 months (Log-rank p=0.089). 20 pts (37%) died during follow-up, with a median time to death from ibrutinib initiation of 11 (IQR: 4,26) months, but there were no statistically significant differences between the groups regarding overall mortality over 24 months (Log-Rank p = 0.209).</span></span></p> <p><strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">Conclusions:</span></span></strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif"> Cardiotoxicity was a common occurrence in our cohort of pts treated with ibrutinib, with AF being the most frequent event. Despite its prevalence, most cardiotoxic events were mild and manageable and not associated with a shorter time to suspension of ibrutinib (p = 0.089) or with greater overall mortality (p = 0.209).</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site